Considering their recent identification of unique processing patterns of apolipoprotein A2 (ApoA2) in patients with pancreatic cancer, researchers undertook this work prospectively evaluating an ApoA2 isoform (“ApoA2-ATQ/AT”), alone and in combination with carbohydrate antigen 19–9 (CA19-9), as an early detection biomarker for pancreatic cancer, for the first time.
In 156 patients with pancreatic cancer and 217 matched controls within the European EPIC cohort, ELISA measurements of CA19-9 and ApoA2-ATQ/AT were performed using plasma samples collected up to 60 months prior to diagnosis. Read more . . .